COVID-19

How pharma can balance remote and in-person activities in Japan

By Mitsu Sumiya, and Ron Quada

March 18, 2021 | Infographic | 4-minute read

How pharma can balance remote and in-person activities in Japan


Understanding how COVID-19 has shifted the workplace for HCPs—both in terms of how and where they provide patient care but also how they engage with pharma sales reps—can help drug manufacturers determine the right timing and channel for their drug-related promotional activities and provide the right support. Japan’s healthcare system is experiencing many of the same challenges that other regions of the world are facing, but to a lesser degree: fewer patient visits and a reduction in treatment initiation, gradual reliance on telehealth and ongoing patient concerns about contracting COVID-19 in transit or at the healthcare facility. 


Test Test Test Test

 

Add insights to your inbox

We’ll send you content you’ll want to read – and put to use.





About the author(s)